Bagai Shaun 4

What Happened

• Shaun Bagai, CEO of RenovoRx, participated in a private placement on March 20, 2026, acquiring 24,300 common shares and an additional 12,150 derivative securities (warrants). The filing shows no per-share price; the issuer reports the aggregate cash paid for the securities was $25,000. This was a purchase (insider buy), which many investors view as a more informative signal than routine sales.

Key Details

• Transaction date: March 20, 2026; filing date: March 24, 2026 (no late-filing flag provided in the data).
• Consideration: Aggregate $25,000 paid for the securities (per footnote).
• Securities acquired: 24,300 common shares (purchase) and 12,150 warrants/derivative securities (reported as a derivative acquisition).
• Shares held of record: 289,057 common shares are held of record by The Bagai Family Trust and were previously reported as directly beneficially held by the reporting person (per footnote).
• Footnotes of note:
  • F1: Confirms the private placement purchase on March 20, 2026 for $25,000 aggregate.
  • F2: The warrants are exercisable immediately and expire on the earlier of March 30, 2029 or 30 days after the issuer reports at least $1.5M in product sales in a quarter (with certain revenue exclusions).
  • F3: 289,057 shares are held of record by The Bagai Family Trust and were previously reported as directly held by Mr. Bagai.
• No indication in the provided data that this filing was late (transactionTimeliness flag not present).

Context

• The derivative portion appears to be warrants that can be exercised into common shares under the terms in F2; they are not immediate common-stock shares until exercised. The small aggregate cash amount ($25k) indicates a relatively modest economic commitment rather than a large stake purchase. Purchases by executives can be interpreted as alignment with the company, but they do not by themselves prove future company performance.